Learn about the latest in multiple myeloma advances with Paul Richardson, MD who will cover the recent American Society of Hematology and European Hematology Association meeting findings.

Dr. Morie Gertz joins the HealthTree Podcast for Multiple Myeloma to share the challenges, treatments and futures of AL amyloidosis and invites amyloidosis patients to join this survey about their diagnosis experience.

Dr. Ola Landgren shares a clinical trial about smoldering myeloma. Join the REVIVE trial study for high-risk smoldering myeloma study here. 

He also share about his research partnership with HealthTree on a personalized medicine study that creates a computerized model of risk prediction and treatment recommendations for newly diagnosed patients. 

This is a study that is open to all myeloma patients regardless of where they are being treated. The only involvement by patients is to sign a consent form and connect their medical records which requires less than 5 minutes of participation. 

Dr. Clifton Mo of Dana Farber Cancer Institue shares a multitude of tools available in the myeloma toolbox. This includes all of the "standard of care" drugs that we are familiar with such as immunomodulators, proteasome inhibitors, steroids, monoclonal antibodies as well as tools in development. 

He reviews triplet combo treatment options at first relapse and his preference to use Kyprolis in the mix, especially when given a more aggressive myeloma. 

Dr. Mo explains how antibody drug conjugates (ADCs) work and how the first ADC, BLENREP, may be making a comeback. He shares how dexamethasone can be reduced or stopped under certain conditions. He explains BCL-2 inhibitors like venetoclax and how they are making their way through clinical trials. 

Dr. Mo describes celmods and how they work and are a promising new class of drugs. He also described how an XPO1 inhibitor called selinexor is being used both with the celmods  and alone as an agent that works well for higher risk myeloma. 

This shows myeloma patients how fortunate we are to have these tools available and speaks to the importance of having a myeloma specialist on your team who can help you make treatment decisions. This can be done alone or in partnership with your local oncologist. There is data that shows that having a specialist on year team leads to longer life. 

Learn how bispecific antibodies are being used in multiple myeloma care and how physicians are helping patients manage side effects using new approaches like fixed-duration therapy.